How GVP Audits Help Overseas MAHs Evaluate Real PV Execution Capability in China
Discover how GVP audits help overseas MAHs evaluate execution capability, vendor oversight, CAPA effectiveness, and pharmacovigilance system performance in China.
MARKETING ARTICLES
For overseas MAHs (Marketing Authorization Holders), one of the biggest challenges in managing pharmacovigilance activities in China is visibility.
From the perspective of global headquarters, the China PV system may appear compliant:
• SOPs are in place
• Training records are completed
• Vendors are appointed
• Reports are submitted
However, regulatory authorities often focus on a deeper question:
Can the local PV system consistently deliver compliant, traceable, and high-quality execution in real-world operations?
This is precisely where risk-based GVP audits become critical.
A well-designed GVP audit does not simply review documentation. It evaluates whether the China pharmacovigilance system has sustainable operational capability and effective quality governance.
Overseas MAHs Need Verifiable Operational Capability — Not Only Documentation
Many overseas MAHs discover a significant gap between “documented compliance” and “operational effectiveness.”
Global teams often review:
• Contracts
• SOPs
• Training completion records
• KPI reports
But regulators increasingly assess whether:
• Processes operate consistently in practice
• Risks are proactively managed
• Escalation pathways function effectively
• CAPA actions prevent recurrence
• Oversight mechanisms remain traceable and sustainable
The key purpose of a GVP audit is therefore not only to confirm compliance status, but to determine whether the local PV system can continuously deliver high-quality outputs under real operational conditions.
Common Execution Gaps in China PV Systems
In practice, operational differences across China PV systems often emerge in multiple areas.
1. Disconnect Between SOPs and Daily Operations
Many organizations maintain comprehensive documentation, but operational execution may remain inconsistent.
Common examples include:
• Superficial deviation investigations
• Incomplete case quality review
• Weak quality control depth
• Inconsistent escalation practices
• Limited documentation of decision-making rationale
This creates a gap between written procedures and actual operational effectiveness.
2. Weak CAPA and Quality System Closure
In some organizations, CAPA activities focus primarily on describing corrective actions without fully addressing root causes.
Effective CAPA systems should demonstrate:
• Root cause analysis
• Preventive action implementation
• Effectiveness verification
• Reduction of recurring issues
Without a complete quality loop, the same operational deficiencies may continue to reappear.
3. Limited Proactive Signal and Risk Management
Some PV systems rely heavily on periodic reporting or external triggers rather than proactive risk evaluation.
Regulators increasingly expect organizations to demonstrate:
• Risk-based thinking
• Traceable signal evaluation
• Timely escalation
• Evidence-supported decision-making
• Ongoing risk monitoring mechanisms
If signal management remains reactive, overseas MAHs may struggle to demonstrate effective pharmacovigilance governance.
4. Insufficient Coordination Across Vendors and Local Stakeholders
In many outsourcing models, responsibilities between:
• PV CROs
• Local responsible persons
• Distributors
• Business partners
• Global safety teams
may appear clear on paper but remain operationally fragmented.
Common weaknesses may include:
• Unclear communication cadence
• Inconsistent quality meetings
• Delayed escalation
• Weak cross-functional coordination
• Insufficient vendor oversight
During inspections or deviations, these coordination gaps can significantly affect response effectiveness.
Regulatory Expectations: MAH Responsibility Does Not Decrease After Outsourcing
From a regulatory perspective, the MAH retains ultimate responsibility for pharmacovigilance activities, even when operational work is outsourced.
As a result, GVP audits increasingly focus on whether the MAH can demonstrate sustainable oversight and effective governance across the entire PV system.
Key audit areas often include:
• Control points across critical PV workflows
• Case collection, assessment, coding, reporting, and follow-up
• Deviation management and change control
• CAPA effectiveness verification
• Training and personnel competency
• Vendor oversight and quality agreements
• Escalation mechanisms and governance pathways
• Risk management aligned with EMA GVP expectations
For overseas MAHs, the ability to demonstrate these capabilities has become increasingly important during inspections, internal governance reviews, and partner oversight activities.
Why Compliance Checks Alone Are Not Enough
Many organizations still treat PV audits as simple compliance checks.
However, a true GVP audit is fundamentally different.
Effective GVP audits focus on:
• Risk-based evaluation
• System effectiveness
• Traceable evidence
• Sustainable governance
• Continuous improvement capability
This distinction is critical because audit conclusions often influence:
• Internal quality committee decisions
• Inspection readiness strategies
• Vendor governance actions
• Resource allocation and remediation priorities
• Long-term compliance planning
A checklist-based audit may identify isolated observations, but it rarely provides meaningful insight into whether the PV system can remain stable under regulatory pressure.
How PV Solutions Limited Supports Overseas MAHs
PV Solutions Limited provides specialized GVP audit and China pharmacovigilance consulting services tailored for overseas MAHs operating in complex local environments.
Our methodology emphasizes practical and usable audit outcomes.
We combine:
• China pharmacovigilance regulatory requirements
• EMA GVP expectations
• ISO QMS methodologies
• Risk management principles
• Operational PV expertise
Our audit approach includes:
• Multi-dimensional assessment of PV system effectiveness
• Risk grading and prioritization
• Actionable remediation recommendations
• CAPA verification planning
• Vendor oversight evaluation
• Governance and escalation pathway assessment
Most importantly, we focus on helping overseas MAHs build sustainable pharmacovigilance governance systems — not simply generating audit reports.
Building Sustainable China PV Governance Through Risk-Based GVP Audits
As China pharmacovigilance requirements continue to mature, overseas MAHs increasingly need visibility into how local PV systems operate in practice.
A structured GVP audit helps organizations:
• Identify hidden operational risks
• Improve vendor governance
• Strengthen inspection readiness
• Enhance traceability and oversight
• Reduce recurring quality issues
• Build sustainable compliance capability
At PV Solutions Limited, we help international pharmaceutical companies transform pharmacovigilance audits into long-term governance and risk management tools for China operations.
Need support evaluating your China PV execution capability or outsourced pharmacovigilance governance?
Contact PV Solutions Limited to discuss risk-based GVP audit solutions tailored for overseas MAHs operating in China.